Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients With Active Class III or IV Lupus Nephritis, Including an Evaluation of Open Label Safety and PK in a Cohort of Pediatric Patients (Aged 5 to < 12)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Diphenhydramine (Primary) ; Methylprednisolone (Primary) ; Mycophenolate mofetil (Primary) ; Obinutuzumab (Primary) ; Paracetamol (Primary) ; Prednisone (Primary)
Indications Lupus nephritis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms POSTERITY
Sponsors Roche

06 Mar 2026 Planned End Date changed from 28 Sep 2029 to 14 Jun 2030.
06 Mar 2026 Planned primary completion date changed from 31 Aug 2027 to 15 Jun 2028.
26 Mar 2025 Planned End Date changed from 31 Aug 2027 to 28 Sep 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com